New protein variants offer fresh path to treating kidney cancer

Researchers have identified novel genetic variants of a growth protein called VEGF that could become new targets for kidney cancer drugs. The finding potentially opens an alternative treatment avenue for renal cell carcinoma, a disease affecting tens of thousands of patients annually and a significant market for oncology therapeutics.

Originaltitel: A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma